The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in China

Abstract

MATRICS Consensus Cognitive Battery (MCCB), packaging 10 tests selected from more than 90 nominated tests, is a method developed by the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) group to evaluate the efficacy of treatments targeting cognitive impairments in schizophrenia. MCCB had been translated into a number of languages, but only the US and Spain had normative data reported. Inconsistency in translation and cultural differences make direct application of MCCB in China problematic. In this study, we administered the battery to a representative community sample based on Chinese population census in 2005 and obtained normative data. The effects of age, gender, education level, and scale of residence area on test performance were examined. The sample included 656 healthy volunteers from six sites in China. At each site, sample was stratified according to age, gender, and educational level, and scale of the area one was born in, grew up in and currently living in was recorded. We found age, gender, and education had significant effects on the normative data for MCCB in China, which are comparable to those found for the original standardized English version in the U.S. and the Spanish version in Spain. Remarkably, the residence scale effects on neuropsychological performance were significant, which should be taking into account when calculating the standardized T score for each subject. The practice effects were minor and test-retest reliability of MCCB was good, which suggests MCCB as an appropriate measure for clinical and research usage in China.

<p>Increased Plasma Kynurenic Acid Levels are Associated with Impaired Attention/Vigilance and Social Cognition in Patients with Schizophrenia</p>

“…For test-retest reliability, the reliability was good (interclass correlation coefficient from 0.73 to 0.94). 29…”

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study

“…The US norm of MCCB was developed by Kern et al12 A Chinese version of this assessment with high reliability and validity was created and further revised by Shi et al13 All examiners who conducted MCCB assessments were trained and certified by the MATRICS group from the US.…”

Verification of virtual reality to evaluate deficiencies in cognitive function among patients with schizophrenia in the remission stage: a cross-sectional study

“…Patients with schizophrenia (SZs) exhibit damaged cognitive function, including reduced attention and memory, and di culties with executive functioning [3]. The MATRICS Consensus Cognitive Battery (MCCB), which includes 10 different cognitive subtests, is an accepted standard for measuring cognitive change in schizophrenia and has been recommended by the United States Food and Drug Administration (FDA) to assess cognitive impairment in schizophrenia [4,5]. It demonstrates excellent reliability and practicality.…”